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Abstract
Background: Treatment-resistant thin endometrium (TTE) during in-vitro fertilization is
a relatively uncommon and challenging problem.
Objective: The primary aim of the study was to assess the TTE rate during frozen
embryo transfer (FET) cycles and the secondary aim was to evaluate the effect of
intrauterine instillation of granulocyte colony stimulating factor (G-CSF) in these cases.
Materials and Methods: In this cross-sectional study, all of the women who underwent
FET cycles with hormonal endometrial preparation in Royan Institute from June 2015
to March 2018 were evaluated and all of the cases with TTE diagnosis (endometrial
thickness < 7 mm after using high doses of estradiol) were included. In the eligible
cases, 300 μgr of G-CSF was infused intrauterine. If the endometrium had not reached
at least a 7-mm, a second infusion was prescribed within 48 hr later.
Results: During the study, 8,363 of FET cycles were evaluated and a total of 30 infertile
patients (0.35%) with TTE diagnosis were detected. Finally, 20 eligible patients were
included. The changes of endometrial thickness after G-CSF therapy were significant
(p < 0.001); however, the endometrial thickness did not reach 7 mm in nine patients
(45%) and the embryo transfer was canceled.
Conclusion: It was found that the rate of TTE during the FET cycle is very low and
intrauterine perfusion of G-CSF has a potential effect to increase the endometrial
thickness in these patients; however, the rate of cancellation was still high and poor
pregnancy outcomes were observed.
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1. Introduction
Endometrial growth is an essential step in
endometrial receptivity and embryo implantation
in assisted reproductive technique cycles (1). A
thin endometrium of < 7 mm is associated with
a decreased odds ratio of achieving pregnancy
whether with pathologic causes or idiopathic cases
(1, 2). In addition, it is a challenging subject
with unclear real prevalence (3). The incidence
rate between less than 1-2% during in-vitro fer-
tilization (IVF) cycles were reported in previous
studies (2, 4). Different types of treatment includ-
ing increased dose of estradiol, low-dose human
chorionic gonadotropin, tamoxifen, pentoxifylline,
vitamin E, l-arginine, low-dose aspirin, nitroglycerin
patches, vaginal sildenafil, acupuncture and neu-
romuscular electric stimulation, intrauterine infu-
sion of granulocyte colony stimulating factor (G-
CSF), and recently stem cell therapy have been
evaluated in previous studies (5). Garcia-Velasco
and colleagues in a review article concluded that
it is not easy to provide a pragmatic, evidence-
based method to assist clinicians and patients
who are confused with the available information
regardingmanagement approaches for a refractory
endometrium (5).
“G-CSF is a glycoprotein and known as
colony stimulating factor 3 produced in
vascular endometrium, macrophages, and other
immunocytes that operate not as a growth factor
but also as a cytokine (5). G-CSF promotes
endometrial stromal cell decidualization via cyclic
adenosine monophosphate mediator by apocrine
and paracrine action and induces proliferation
and differentiation of the human endometrium”
(5). In medicine recombinant, G-CSF was used
in immunology for various indications for a long
time (6). It is a pro-angiogenic mediator and
increases type 2 T helper cell cytokine secretion,
recruitment of dendritic and T regulatory cells
(6, 7). According to previous clinical studies, G-
CSF can be considered as a factor preventing
repeated miscarriages and implantation failures
(8-10), and it has no impact on the chromosomal
constitution of human embryos (11). From the first
case report study by Gleicher and co-workers in
2011 (4), until now, five studies in IVF (12-16) and
four in FET cycles (3, 6, 17, 18) have evaluated
the effect of intrauterine infusion of G-CSF on
thin endometrium; since the reported results have
been controversial.
The present study was conducted at the Royan
Institute to assess the treatment-resistant thin
endometrium rate during FET cycles with hormonal
endometrial preparation (as primary aim) and to
evaluate the effect of intrauterine instillation of G-
CSF in these cases (as secondary aim).
2. Materials and Methods
In this cross-sectional study, we evaluated all
of the women who underwent frozen embryo
transfer (FET) cycles with hormonal endometrial
preparation at the Royan Institute from June
2015 to May 2018, and all eligible cases with
treatment-resistant thin endometrium diagnosis
were included. The women aged 20-40 years with
previously canceled at least one cycle because of
thin unresponsive endometrium (< 7 mm) during
IVF or FET programs who had written consent
to participate were included in the study. Other
uterine abnormalities (such as Asherman’s syn-
drome, fibroids, polyps, and adenomyosis diag-
nosis), cases with contraindications for G-CSF
treatment (sickle cell disease, chronic renal and
respiratory diseases…) and treatment cycles with
embryo donation or prenatal genetic screening
were excluded.
All women received three estradiol valerate
tablet (2 mg, Aburaihan Co., Tehran, Iran) daily
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and low-dose aspirin from the second or third day
of the menstrual cycle. The Endometrial thickness
measurement (at its thickest part in the longitudinal
axis of uterine) was carried out by ultrasonogra-
phy, 9 or 10 days later. When the endometrial
thickness was < 7 mm after using high doses
of estradiol (8 mg), the same ultrasonographers
measured it repeatedly for three times to approve
thin endometrium, and the average size of the
three different measurements was accepted. When
the thin endometrium was diagnosed, the G-CSF
infusion was performed according to methods pre-
viously described by Gleicher et al. in their study
(12). In summary, the content of the G-CSF ampule
(300 mcg/1ml) (NeupogenTM, Filgastrim, Amgen
Inc., Thousand Oaks, Canada) was aspirated into
a 1-ml insulin syringe, and it was inserted to the
endometrial cavity using a soft catheter (Labotec,
Gottingen Germany); then the G-CSF was gently
infused, while the catheter was slowly ambulated
back and forth. Two days later, the thickness
of endometrium was measured and if it was at
least 7 mm, the patient received 100 mg intra-
muscular progesterone in oil (50 mg; Aburaihan
Co., Tehran, Iran) for three days. According to
women’s age and the quality of embryos, two or
three cleavage stage embryos were transferred.
If not, a second, identical infusion of G-CSF was
done and then two or three days later, the
endometrial thickness was evaluated again, and if
it was less than 7 mm, the embryo transfer was
canceled. All endometrial thickness measurements
and intrauterine infusions have been performed by
a specialist.
2.1. Ethical consideration
The research protocol was approved by the Insti-
tutional Review Board and the Ethics Committee
of the Royan Institute (Ethics code/94/178). Each
participating women signed informed consent.
2.2. Statistical analysis
Data was statistically analyzed by using Sta-
tistical Package for the Social Sciences (SPSS
Inc., Chicago, Illinois, USA) software version 20.
Categorical data were expressed as number and
percentage and numerical data as mean and
standard deviation. The statistical analyses for
parametric data were performed with the use
of a paired t-test to compare means endome-
trial thickness in patients before and after treat-
ment according to the results of the Kolmogorov-
Smirnov normality test for endometrial thickness.
The level of statistical significance was set at p <
0.05.
3. Results
During the study period, 8,363 FET cycles were
evaluated and a total of 30 infertile patients (0.35%)
with treatment-resistant thin endometrium diag-
nosis were detected, finally, 20 eligible patients
were satisfied to receive the G-CSF therapy.
Two patients did not agree to participate and
eight patients did not meet the inclusion crite-
ria of the study. The basic and demographic
characteristics of patients are presented in Table
I, Table II shows the changes in endometrial
thickness after treatment with G-CSF. The mean
of endometrial thickness at the time of infusion
was 5.35 ± 1.06 mm, after intrauterine instilla-
tion of G-CSF, the mean of endometrium thick-
ness was 6.52 ± 1.10 and the changes were
significant (p < 0.001). Despite the increase in
endometrial thickness after G-CSF injection, the
endometrial thickness did not reach 7 mm or more
in nine patients (45%) and the embryo transfer
was canceled. Therefore, 11 patients had embryo
transfer and no case of positive pregnancy was
reported.
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Table I. Demographic characteristics of study participate (n = 20)
Variables Outcome
Age (yr)* 35.2 ± 4.7
BMI (Kg/m2)* 26.2 ± 4.2
Basal serum level of LH* 5.3 ± 3.5
Basal serum level of FSH (mIU/ml)* 5.9 ± 1.4
Serum level of Prolactin (mIU/L)* 169.2 ± 147.7
Basal serum level of Estradiol (pg/ml)* 50.2 ± 43.3
Serum level of TSH (uU/ml)* 1.8 ± 0.7
Serum level of AMH (ng/ml)* 5.8 ± 4.0
Cause of infertility
Ovulatory** 7 (35%)
Uterine factor** 1 (5%)
Male factor** 9 (45%)
Unexplained** 4 (20%)
Tuboperitoneal** 2 (5%)
Failed prior IVF cycles (n)* 1.4 ± 0.85
Duration of infertility (yr)* 8.1 ± 6.5
Prior history of a thin endometrium* 1.1 ± 0.36
*Data presented as Mean ± SD; **data presented as n (%)
Descriptive statistics are used to describe the basic features of the data
BMI: Body mass index; LH: Luteinizing hormone; FSH: Follicle stimulating hormone; TSH: Thyroid stimulating hormone; AMH:
Anti-Müllerian hormone; IVF: In-vitro fertilization
Table II. Endometrial thickness in patients before and after treatment with G-CSF (n = 20)
Variables Outcome P-value
Endometrial thickness at the day of G-CSF infusion 5.35 ± 1.06
Endometrial thickness at the day of embryo transfer 6.52 ± 1.10
Δ Endometrial thickness 1.173 ± 1.10 < 0.001*
Data presented as Mean ± SD, Paired sample t-test was used for analysis, G-CSF: Granulocyte colony stimulating factor
4. Discussion
In the present study, the incidence rate of thin
endometrium during FET cycle in our institute was
estimated to be 0.35%, which is almost similar to
the rate of thin endometrium in IVF cycles (< 1%)
reported by Al-Ghamdi and colleagues (19). It has
been found that intrauterine injection of G-CSF
in patients with unresponsive thin endometrium
diagnosis can improve the endometrial thickness,
but it failed to find out its effect on pregnancy.
However, multiple factors affect pregnancy and
endometrial receptivity and endometrial thickness
are only a quantitative criterion; poor pregnancy
outcomes in the present study can be due to that
the averages of women’s age and BMI were higher
than those in other studies.
After the first case report study by Gleicher
and co-workers (4), four case-series studies have
evaluated the effect of intrauterine infusion of 300
μg of G-CSF in patients with thin endometrium
diagnosis at the day of ovum pickup and reported
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a significant positive impact on improving endome-
trial thickness (12, 14-16). However, Check et al.
in a small number of patients with unresponsive
thin endometrium did not find significant effect
after intrauterine infusion of G-CSF (20). Recently,
Barad and colleagues in a randomized clinical trial
assessed 73 normal patients during IVF and con-
cluded that in normal IVF patients, G-CSF has no
impact on the endometrial thickness, implantation
rates, and clinical pregnancy rates (13).
A few studies evaluated the efficacy of
intrauterine instillation of G-CSF for improving
endometrial thickness in FET cycles, and yet the
findings remain controversial. At first, Li et al. in a
prospective study found no significant differences
in the endometrial thickness, implantation, and
clinical pregnancy rates between patients treated
with 100 μg of G-CSF and the control subjects
(3). Besides, Eftekhar and co-workers in a non-
randomized clinical study assessed 68 patients
with thin endometrium and reported no significant
improvement in endometrial thickness; it is
worth noting that the clinical pregnancy rate
was higher in the G-CSF group than that in the
control group (18). Later, Xu and colleagues in
a prospective study divided 30 patients with
thin endometrium diagnosis in two treatment
subgroup (16 patients with G-CSF and 14 patients
with G-CSF plus endometrial scratch) (17). After
treatment in both the groups, the endometrial
thickness increased significantly. The G-CSF
with endometrial scratch subgroup associated
with nominally higher rates of clinical pregnancy
and live birth in comparison with the G-CSF
only subgroup; though the differences were
non-significant (17). Finally, it concluded that
endometrial scratch did not damage the G-CSF
action for thin endometrium and lean toward
a better pregnancy and live birth rates. They
recommended embryo transfer cancellation and
G-CSF therapy in subsequent FET cycles for
patients with a thin endometrium (17). In contrast,
Kunicki and co-workers (6) evaluated 62 women
with thin unresponsive endometrium (29 patients
treated with a G-CSF infusion and 33 cases who
opted out of the study considered as controls).
It was found that G-CSF infusion leads to an
improvement in endometrium thickness but has
no beneficial effect on clinical pregnancy and live
birth rates. Therefore, although the case series and
non-randomized studies are promising, the only
published randomized clinical trial failed to find
any effect on clinical outcome. Reliable evidence
for the beneficial effect of G-CSF in improving
endometrial receptivity is still limited (5) and more
data is warranted for a definitive conclusion in this
regard.
The first limitation of the study is a relatively small
cohort size; although, in most studies conducted in
this area (3, 12, 14-16, 18), the patients’ number in
the experimental group (G-CSF treatment) was less
than 40, due to the low prevalence of treatment-
resistant thin endometrium (0.1-2%). Therefore, the
evaluation of this number of patients can be
valuable and represent a ”small piece” to increase
the research about this type of treatment. The
second limitation is the lack of a control group.
The strength of this study was to evaluate the
incidence rate of thin endometrium during FET
cycles since there is very limited data in this
regard.
5. Conclusion
It was found that the rate of treatment-resistant
thin endometrium during the FET cycle with
hormonal endometrial preparation is very low and
G-CSF has a potential effect to increase the
endometrial thickness in these patients; however,
the rate of cancellation was still high and poor
pregnancy outcomes were observed.
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